Maike de Wit

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.4K citations · Full text

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Nanomedicine, Oncology, Pancreatic Cancer +8

Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group

Andreas Engert, Petra Schiller, Andreas Josting et al. · Journal of Clinical Oncology · 2003 · 456 citations

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Corinne Faivre‐Finn, David Vicente, Takayasu Kurata et al. · Journal of Thoracic Oncology · 2021 · 455 citations · Full text